Search results
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 5 days agoAnito-cel, which utilizes Arcellx’s novel D-Domain binder, is a BCMA CAR T-cell therapy, a type of...
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Zacks via Yahoo Finance· 12 hours agoAllogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 9 hours ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference
Breakthrough therapies are saving lives. Can we afford them?
San Jose Mercury News· 3 days agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial P
Guru Focus· 4 days agoThe clinical-stage biopharmaceutical company, known for its innovative programmed cellular immunotherapies for cancer and autoimmune disorders, reported a mix of financial challenges and significant ...
Remarkable cancer breakthrough shows woman's brain tumor almost disappear in just five days
UNILAD· 2 days agoA team of researchers have revealed the 'dramatic responses' three cancer patients had to a new type...
Does Valley Children’s prioritize patient care or profitability? It’s a fair question | Opinion
Fresno Bee via Yahoo News· 6 days agoEven joyous. Once the programs get established and certified, patients in need of bone marrow...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 5 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 5 days agoAnito-cel is a B-cell maturation antigen chimeric antigen receptor (BCMA CAR) T-cell therapy. The...
Coya Therapeutics Reports First Quarter 2024 Financial Results
Guru Focus· 4 days agoOn May 9, 2024, Coya Therapeutics Inc (COYA, Financial), a trailblazer in biologics for enhancing regulatory T cell function, disclosed its financial outcomes ...